Orion Corporation signs European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone

NEXT STORY
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results
PREV STORY
Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease

author_avatar
NASDAQ Market News

Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017

Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project; Curetis Announces ...

author_avatar
NASDAQ Market News

Active Biotech’s partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

PRESS RELEASE Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces ...

author_avatar
NASDAQ Market News